NLNoralane M. Lindor

Noralane M. Lindor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noralane M. Lindor has a total of 488 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplemental Table 1 from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History

    by Daniel J. Weisenberger, A. Joan Levine, Tiffany I. Long, Daniel D. Buchanan, Rhiannon Walters, Mark Clendenning, Christophe Rosty, Amit D. Joshi, Mariana C. Stern, Loic Le Marchand, et al.

    Supplemental Table 1. Distribution of CIMP status1 by selected characteristics

  • Open Access

    Data from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History

    by Daniel J. Weisenberger, A. Joan Levine, Tiffany I. Long, Daniel D. Buchanan, Rhiannon Walters, Mark Clendenning, Christophe Rosty, Amit D. Joshi, Mariana C. Stern, Loic Le Marchand, et al.

  • Open Access

    Data from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History

    by Daniel J. Weisenberger, A. Joan Levine, Tiffany I. Long, Daniel D. Buchanan, Rhiannon Walters, Mark Clendenning, Christophe Rosty, Amit D. Joshi, Mariana C. Stern, Loic Le Marchand, et al.

    Background: The CpG island methylator phenotype (CIMP) represents a subset of colorectal cancers characterized by widespread aberrant DNA hypermethylation at select CpG islands. The risk factors and environmental exposures contributing to etiologic heterogeneity between CIMP and non-CIMP tumors are not known.Methods: We measured the CIMP status of 3,119 primary population-based colorectal cancer tumors from the multinational Colon Cancer Family Registry. Etiologic heterogeneity was assessed by a case–case study comparing risk factor frequency of colorectal cancer cases with CIMP and non-CIMP tumors using logistic regression to estimate the case–case odds ratio (ccOR).Results: We found associations between tumor CIMP status and MSI-H (ccOR = 7.6), BRAF V600E mutation (ccOR = 59.8), proximal tumor site (ccOR = 9; all P < 0.0001), female sex [ccOR = 1.8; 95% confidence interval (CI), 1.5–2.1], older age (ccOR = 4.0 comparing over 70 years vs. under 50; 95% CI, 3.0–5.5), and family history of CRC (ccOR = 0.6; 95% CI, 0.5–0.7). While use of NSAIDs varied by tumor CIMP status for both males and females (P = 0.0001 and P = 0.02, respectively), use of multivitamin or calcium supplements did not. Only for female colorectal cancer was CIMP status associated with increased pack-years of smoking (Ptrend < 0.001) and body mass index (BMI; Ptrend = 0.03).Conclusions: The frequency of several colorectal cancer risk factors varied by CIMP status, and the associations of smoking and obesity with tumor subtype were evident only for females.Impact: Differences in the associations of a unique DNA methylation–based subgroup of colorectal cancer with important lifestyle and environmental exposures increase understanding of the molecular pathologic epidemiology of this heavily methylated subset of colorectal cancer. Cancer Epidemiol Biomarkers Prev; 24(3); 512–9. ©2015 AACR.

  • Open Access

    Data from A Randomized Trial to Increase Colonoscopy Screening in Members of High-Risk Families in the Colorectal Cancer Family Registry and Cancer Genetics Network

    by Jan T. Lowery, Nora Horick, Anita Y. Kinney, Dianne M. Finkelstein, Kathleen Garrett, Robert W. Haile, Noralane M. Lindor, Polly A. Newcomb, Robert S. Sandler, Carol Burke, et al.

  • Open Access

    Supplemental Table 1 from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History

    by Daniel J. Weisenberger, A. Joan Levine, Tiffany I. Long, Daniel D. Buchanan, Rhiannon Walters, Mark Clendenning, Christophe Rosty, Amit D. Joshi, Mariana C. Stern, Loic Le Marchand, et al.

    Supplemental Table 1. Distribution of CIMP status1 by selected characteristics

  • Open Access

    Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study

    by Aayah Nounu, Rebecca C. Richmond, Isobel D. Stewart, Praveen Surendran, Nicholas J. Wareham, Adam Butterworth, Stephanie J. Weinstein, Demetrius Albanes, John A. Baron, John L. Hopper, et al.

    Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. Aspirin (acetylsalicylic acid, that rapidly deacetylates to SA) is an effective primary and secondary chemopreventive agent. Through a Mendelian randomization (MR) approach, we aimed to address whether levels of SA affected CRC risk, stratifying by aspirin use. A two-sample MR analysis was performed using GWAS summary statistics of SA (INTERVAL and EPIC-Norfolk, N = 14,149) and CRC (CCFR, CORECT, GECCO and UK Biobank, 55,168 cases and 65,160 controls). The DACHS study (4410 cases and 3441 controls) was used for replication and stratification of aspirin-use. SNPs proxying SA were selected via three methods: (1) functional SNPs that influence the activity of aspirin-metabolising enzymes; (2) pathway SNPs present in enzymes’ coding regions; and (3) genome-wide significant SNPs. We found no association between functional SNPs and SA levels. The pathway and genome-wide SNPs showed no association between SA and CRC risk (OR: 1.03, 95% CI: 0.84–1.27 and OR: 1.08, 95% CI: 0.86–1.34, respectively). Results remained unchanged upon aspirin use stratification. We found little evidence to suggest that an SD increase in genetically predicted SA protects against CRC risk in the general population and upon stratification by aspirin use.


  • Increasing access to genomic medicine: a study examining perspectives of Latinos receiving genomic screening at a Federally Qualified Health Center

    by Gabriel Shaibi, Alex Lee, Jamie O’bYrne, Idali Cuellar, Erica Sutton, Valentina Hernandez, Noralane Lindor, Davinder Singh, Iftikhar Kullo, Richard Sharp

  • Open Access

    Returning Results in the Genomic Era: Initial Experiences of the eMERGE Network

    by Georgia L. Wiesner, Alanna Kulchak Rahm, Paul Appelbaum, Sharon Aufox, Sarah T. Bland, Carrie L. Blout, Kurt D. Christensen, Wendy K. Chung, Ellen Wright Clayton, Robert C. Green, et al.

    A goal of the 3rd phase of the Electronic Medical Records and Genomics (eMERGE3) Network was to examine the return of results (RoR) of actionable variants in more than 100 genes to consenting participants and their healthcare providers. Each of the 10 eMERGE sites developed plans for three essential elements of the RoR process: Disclosure to the participant, notification of the health care provider, and integration of results into the electronic health record (EHR). Procedures and protocols around these three elements were adapted as appropriate to individual site requirements and limitations. Detailed information about the RoR procedures at each site was obtained through structured telephone interviews and follow-up surveys with the clinical investigator leading or participating in the RoR process at each eMERGE3 institution. Because RoR processes at each of the 10 sites allowed for taking into account differences in population, disease focus and institutional requirements, significant heterogeneity of process was identified, including variability in the order in which patients and clinicians were notified and results were placed in the EHR. This heterogeneity in the process flow for eMERGE3 RoR reflects the “real world” of genomic medicine in which RoR procedures must be shaped by the needs of the patients and institutional environments.


  • Open Access

    Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report

    by Toni T. Seppälä, Aysel Ahadova, Mev Dominguez-Valentin, Finlay Macrae, D. Gareth Evans, Christina Therkildsen, Julian Sampson, Rodney Scott, John Burn, Gabriela Möslein, et al.

    Recent epidemiological evidence shows that colorectal cancer (CRC) continues to occur in carriers of pathogenic mismatch repair (path_MMR) variants despite frequent colonoscopy surveillance in expert centres. This observation conflicts with the paradigm that removal of all visible polyps should prevent the vast majority of CRC in path_MMR carriers, provided the screening interval is sufficiently short and colonoscopic practice is optimal. To inform the debate, we examined, in the Prospective Lynch Syndrome Database (PLSD), whether the time since last colonoscopy was associated with the pathological stage at which CRC was diagnosed during prospective surveillance. Path_MMR carriers were recruited for prospective surveillance by colonoscopy. Only variants scored by the InSiGHT Variant Interpretation Committee as class 4 and 5 (clinically actionable) were included. CRCs detected at the first planned colonoscopy, or within one year of this, were excluded as prevalent cancers. Stage at diagnosis and interval between last prospective surveillance colonoscopy and diagnosis were available for 209 patients with 218 CRCs, including 162 path_MLH1, 45 path_MSH2, 10 path_MSH6 and 1 path_PMS2 carriers. The numbers of cancers detected within < 1.5, 1.5–2.5, 2.5–3.5 and at > 3.5 years since last colonoscopy were 36, 93, 56 and 33, respectively. Among these, 16.7, 19.4, 9.9 and 15.1% were stage III–IV, respectively (p = 0.34). The cancers detected more than 2.5 years after the last colonoscopy were not more advanced than those diagnosed earlier (p = 0.14). The CRC stage and interval since last colonoscopy were not correlated, which is in conflict with the accelerated adenoma-carcinoma paradigm. We have previously reported that more frequent colonoscopy is not associated with lower incidence of CRC in path_MMR carriers as was expected. In contrast, point estimates showed a higher incidence with shorter intervals between examinations, a situation that may parallel to over-diagnosis in breast cancer screening. Our findings raise the possibility that some CRCs in path_MMR carriers may spontaneously disappear: the host immune response may not only remove CRC precursor lesions in path_MMR carriers, but may remove infiltrating cancers as well. If confirmed, our suggested interpretation will have a bearing on surveillance policy for path_MMR carriers.


  • Open Access

    Non- BRCA familial breast cancer: review of reported pathology and molecular findings

    by Michael G. Keeney, Fergus J. Couch, Daniel W. Visscher, Noralane M. Lindor